These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 39372415)

  • 1. RNA modifications in cancer immune therapy: regulators of immune cells and immune checkpoints.
    Qin X; Liu H; Zhang Q; Che Y; Lei T; Tang F; Hu Q
    Front Immunol; 2024; 15():1463847. PubMed ID: 39372415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer.
    Li G; Liu X; Gu C; Ma G; Li S; Ma Z; Xiong Y; Jiang Y; Huang Q; Wu J; Wu Z; Liao W; Wu Q; Shi M
    J Transl Med; 2024 Aug; 22(1):718. PubMed ID: 39097734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-coding RNA and immune-checkpoint inhibitors: friends or foes?
    Shek D; Read SA; Akhuba L; Qiao L; Gao B; Nagrial A; Carlino MS; Ahlenstiel G
    Immunotherapy; 2020 May; 12(7):513-529. PubMed ID: 32378480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK Cell-Based Immune Checkpoint Inhibition.
    Khan M; Arooj S; Wang H
    Front Immunol; 2020; 11():167. PubMed ID: 32117298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
    Pan J; Huang T; Deng Z; Zou C
    Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
    Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
    ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.
    Tong H; Wei H; Smith AO; Huang J
    Front Immunol; 2021; 12():802049. PubMed ID: 35069586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
    Meng Q; He J; Zhong L; Zhao Y
    Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
    Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
    Front Immunol; 2021; 12():688215. PubMed ID: 34305920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies.
    Pitts SC; Schlom J; Donahue RN
    J Exp Clin Cancer Res; 2024 May; 43(1):155. PubMed ID: 38822401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
    Saleh R; Toor SM; Sasidharan Nair V; Elkord E
    Front Immunol; 2020; 11():1469. PubMed ID: 32760400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
    Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N
    J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
    Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer-Narrative Review.
    Poniewierska-Baran A; Sobolak K; Niedźwiedzka-Rystwej P; Plewa P; Pawlik A
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
    Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
    Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of extracellular vesicle immune checkpoints in cancer.
    Zhang W; Ou M; Yang P; Ning M
    Clin Exp Immunol; 2024 May; 216(3):230-239. PubMed ID: 38518192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.